Top-News

Travere Therapeutics Aktie News

Aktie
WKN:  A2QHYP ISIN:  US89422G1076 US-Symbol:  TVTX Branche:  Biotechnologie Land:  USA
34,90 $
-0,43 $
-1,22%
29,975 € 18:41:12 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,65 Mrd. €
Streubesitz
-
KGV
-4,50
Index-Zuordnung
-

Travere Therapeutics News

26.09.25 - PR Newswire
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy PR Newswire
02.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
22.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
12.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
07.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
01.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
26.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
20.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
13.02.25 - Boersify
Travere Therapeutics Aktie: Innovation rollt weiter!
Die Aktie des Biotech-​Unternehmens Travere Therapeutics verzeichnet derzeit bedeutende Bewegungen, während mehrere hochrangige Führungskräfte Aktienverkäufe ...
05.02.25 - Börse-Global
Travere Therapeutics Aktie: Neue Marktgegebenheiten analysiert
Die Aktie des Biopharma-​Unternehmens Travere Therapeutics verzeichnet derzeit eine bemerkenswerte Entwicklung, wobei mehrere hochrangige Führungskräfte zeitgleich ...

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »